Presented Phase 1 denikitug at #AACR26. Anti-CCR8 mAb is pharmacologically active at ≥10 mg: CCR8+ intratumoral Treg depletion and Teff activation on paired biopsies. Antitumor responses in heavily pretreated pts, including anti-PD-(L)1 refractory. Manageable safety. Supports mono and combo development. @BIDMC_CancerCtr @DanaFarber